Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with Bayer

ORIC Pharmaceuticals is a clinical-stage biotech with no product revenue, evidenced by zero revenue across all reported quarters. The company's fundamental outlook hinges on the success of its oncology pipeline, with R&D expenses climbing from $22.0M in 2024Q1 to $36.3M in 2026Q2, driving net losses to $41.5M in…
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 16, 2026 | -$0.44-12.2% vs -$0.39 | — vs — |
Q3 2026 Aug 3, 2026 | -$0.38-5.7% vs -$0.36 | — vs — |
Q2 2026 May 4, 2026 | -$0.34-6.0% vs -$0.32 | — vs — |
Q1 2026 Feb 23, 2026 | -$0.30+11.8% vs -$0.34 | — vs — |
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with Bayer

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 2, 2026 (the “Grant Date”), ORIC granted a total of 14,800 non-qualified stock options and 2,400 restricted stock units to one new non-executive employee who began their employment with ORIC in October 2026.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in November:
Oric Pharmaceuticals, Inc. (NASDAQ: ORIC - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $11.14 and traded as low as $8.88. Oric Pharmaceuticals shares last traded at $8.95, with a volume of 6,942,854 shares trading hands. Wall Street Analysts Forecast Growth
Benchmark ORIC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ORIC Pharmaceuticals, Inc. (ORIC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.00 | $828.14M | -5.55 | — | — | -40.99% | — | |
| $121.52 | $10B | -34.81 | -16.72% | -341.87% | -22.39% | — | |
| $22.11 | $3.6B | -18.49 | 48.29% | — | -30.34% | — | |
| $305.06 | $8.5B | -24.77 | -100% | — | -29.41% | — | |
| $6.82 | $440.03M | -46.94 | -0.3% | -3.45% | -2% | — | |
| $15.40 | $1.98B | 6.62 | 20.38% | 97.68% | 51.92% | — |
ORIC Pharmaceuticals, Inc. (ORIC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ORIC Pharmaceuticals, Inc. (ORIC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jul 30, 2026·SEC
Jun 22, 2026·SEC
Get notified when ORIC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ORIC Pharmaceuticals, Inc. (ORIC) stock FAQ — growth, dividends, profitability & financials explained
No. ORIC Pharmaceuticals, Inc. (ORIC) reported a net loss of $155.8M over the trailing twelve months.
ORIC Pharmaceuticals, Inc. (ORIC) had a return on equity (ROE) of -41.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
ORIC Pharmaceuticals, Inc. (ORIC) had negative free cash flow of $128.9M over the trailing twelve months.